Preferred Label : Etesevimab;
NCIt synonyms : Anti-COVID-19 Monoclonal Antibody JS016; Anti-SARS-CoV-2 Monoclonal Antibody JS016; Anti-COVID-19 Spike Protein Monoclonal Antibody JS016;
NCIt related terms : Monoclonal antibodies against SARS-CoV-2: etesevimab;
NCIt definition : An Fc-modified neutralizing, recombinant, human monoclonal antibody directed against
the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against
Coronavirus disease 2019 (COVID-19). Upon administration of etesevimab, this agent
specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks
viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2.
This may slow the progression of the disease and accelerate recovery, and may also
provide temporary protection against infection with SARS-CoV-2. S-protein, usually
found on the surface of SARS-CoV-2, plays an essential role in the infection pathway
of the SARS-CoV-2 virus.;
UNII : N7Q9NLF11I;
CAS number : 2423948-94-9;
Molecule name : JS 016; JS-016;
NCI Metathesaurus CUI : CL1407894;
Origin ID : C173977;
UMLS CUI : C5421804;
CISMeF manual mappings
Semantic type(s)
UMLS correspondences (same concept)
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
https://www.ansm.sante.fr/actualites/anticorps-monoclonaux-lansm-permet-lutilisation-en-acces-precoce-de-deux-bitherapies-contre-la-covid-19
2021
false
false
false
France
French
scientific and technical information
drug information
antibodies, monoclonal
adult
Casirivimab/Imdevimab
Casirivimab
Imdevimab
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
Bamlanivimab
Etesevimab
aged
spike glycoprotein, coronavirus
france
drug monitoring
risk
drug combinations
casirivimab and imdevimab drug combination
COVID-19
COVID-19
casirivimab
imdevimab
casirivimab and imdevimab
drug combinations
antibodies, monoclonal, humanized
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal
product form)
casirivimab and imdevimab drug combination
---
https://ansm.sante.fr/actualites/covid-19-lacces-aux-bitherapies-danticorps-monoclonaux-contre-la-covid-19-est-elargi
2021
false
false
false
France
French
drug information
drug combinations
antibodies, monoclonal, humanized
adult
Casirivimab/Imdevimab
Bamlanivimab
Etesevimab
guidelines for drug use
casirivimab
imdevimab
bamlanivimab
etesevimab
casirivimab and imdevimab drug combination
COVID-19
casirivimab and imdevimab drug combination
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal
product form)
---
https://ansm.sante.fr/uploads/2021/03/16/20210315-atuc-bamlanivimab-etesevimab-put-2.pdf
2021
false
false
false
France
French
drug therapy, combination
guideline
health occupations
professional role
risk management
continuity of patient care
drug monitoring
infusions, intravenous
pharmacovigilance
information dissemination
drug prescriptions
Therapy cessation
adult
aged
antibodies, monoclonal, humanized
Etesevimab
Bamlanivimab
spike glycoprotein, coronavirus
adverse drug reaction reporting systems
bamlanivimab
bamlanivimab
pneumonia, viral
coronavirus infections
pandemics
pneumonia, viral
coronavirus infections
pandemics
coronavirus infections
COVID-19
COVID-19
antibodies, monoclonal, humanized
---